Golimumab for the treatment of psoriatic arthritis

Golimumab is recommended as an option for the treatment of active and progressive psoriatic arthritis in adults only if:

• it is used as described for other tumour necrosis factor (TNF) inhibitor treatments in NICE's technology appraisal guidance on etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis and

• the manufacturer provides the 100 mg dose of golimumab at the same cost as the 50 mg dose.

When using the Psoriatic Arthritis Response Criteria (PsARC; as set out in NICE's technology appraisal guidance on etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis), healthcare professionals should take into account any physical, sensory or learning disabilities, or communication difficulties that could affect a person's responses to components of the PsARC and make any adjustments they consider appropriate.